Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Roland Schott"'
Autor:
Nicolas Girard, Gaëtane Simon, Maurice Pérol, Thomas Filleron, Christos Chouaid, Roland Schott, Matthieu Carton, Clarisse Audigier Valette, Mathieu Robain, Xavier Quantin, Didier Debieuvre, Radj Gervais, Hervé Lena, Bruno Coudert
Publikováno v:
Lung Cancer. 162:119-127
Background Cisplatin-based chemotherapy administered concurrently to thoracic radiation therapy is the recommended treatment for fit patients with unresectable stage III NSCLC. The aim of this study was to describe patient profiles and clinical outco
Autor:
Nicolas Girard, Eric Pichon, David Planchard, Didier Debieuvre, Radj Gervais, Gaëlle Chenuc, Pascale Dubray-Longeras, J. Otto, Eric Dansin, Hervé Lena, Anne Madroszyk, Maurice Pérol, Thomas Filleron, Xavier Quantin, Lise Bosquet, Gaëtane Simon, Coureche Kaderbhai, Sophie Cousin, Sandrine Hiret, Christelle Clément-Duchêne, Christos Chouaid, Roland Schott
Publikováno v:
Targeted Oncology. 16:801-811
In Europe, few data regarding the characteristics of EGFR exon 20 insertion (20ins) mutations in non-small cell lung cancer (NSCLC) are available. Using a large real-world cohort, we assessed the incidence, characteristics, and outcomes of patients w
Autor:
Nathalie Baize, Christos Chouaid, Lionel Falchero, Patrick Saulnier, Jean-Bernard Auliac, Roland Schott, Groupe Français de Pneumo-Cancérologie – investigators, Laurent Greillier, R. Lamy, Hervé Le Caer, Jacques Letreut, Jacky Crequit, Gwenaelle Le Garff, A. Madroszyk, Radj Gervais, Margaux Geier, Isabelle Monnet, Patrick-Aldo Renault, Alain Vergnenegre, Henri Berard, Eric Dansin, H. Janicot, Hervé Lena
Publikováno v:
The Lancet Oncology. 21:1224-1233
Summary Background Topotecan is currently the only drug approved in Europe in a second-line setting for the treatment of small-cell lung cancer. This study investigated whether the doublet of carboplatin plus etoposide was superior to topotecan as a
Autor:
Gilles Robinet, Christos Chouaid, Radj Gervais, Roland Schott, Florian Guisier, Chantal Decroisette, Jean-Bernard Auliac, Olivier Bylicki, Charles Ricordel, Laurent Greillier, Maurice Pérol, Benjamin Besse, Renaud Descourt
Publikováno v:
Future Oncology
Future Oncology, 2021, 17 (23), pp.3007-3016. ⟨10.2217/fon-2020-1202⟩
Future Oncology, 2021, 17 (23), pp.3007-3016. ⟨10.2217/fon-2020-1202⟩
Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer withoutLay abstract Non-small-cell lung cancer (NSCLC) is the most frequent type of lung cancer. Most NSCLC patients are diagnosed wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62d4948a536b358f6ce91b90b9bc53c5
https://inria.hal.science/hal-03526346
https://inria.hal.science/hal-03526346
Autor:
Anne Marie Chiappa, Isabelle Monnet, Radj Gervais, Christos Chouaid, Alain Vergnenegre, S. Vieillot, Jean Bernard Auliac, Roland Schott, Gilles Robinet, Laurent Greillier, Lionel Falchero, Anne Madroszyk, R. Lamy, Pascal Thomas, Charles Ricordel, Samir Abdiche, Stephane Chouabe, Henri Berard, Chantal Decroisette
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, SAGE Journals, 2021, 13, pp.175883592110069. ⟨10.1177/17588359211006983⟩
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, SAGE Journals, 2021, 13, pp.175883592110069. ⟨10.1177/17588359211006983⟩
Background: The role and timing of whole or stereotaxic brain radiotherapy (BR) in patients with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases (aBMs) are not well established. This study investigates whether deferring
Publikováno v:
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-5 (2019)
Journal of Medical Case Reports
Journal of Medical Case Reports
Background Oligodendroglioma is a rare type of primary brain tumor which, like other malignant gliomas, metastasizes very rarely even when in high-grade form. Case report A 36-year-old white man diagnosed 29 months previously as having 1p/19q codelet
Autor:
Alexis B. Cortot, David Planchard, Hélène Doubre, Bénédicte Mastroianni, Sylvestre Le Moulec, Florian Guisier, Lionel Falchero, Jennifer Arrondeau, Aldo Renault, Isabelle Monnet, Laurent Greillier, Marie Wislez, L. Gérinière, Jean Bernard Auliac, Chantal Decroisette, Maurice Pérol, Eric Pichon, Catherine Daniel, Christos Chouaid, Roland Schott
Publikováno v:
Lung Cancer
Lung Cancer, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, Elsevier, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, Elsevier, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
International audience; Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in clinical trials. However, data on efficacy of osimert
Autor:
Didier Debieuvre, Radj Gervais, Bastien Cabarrou, Charles Ricordel, Maurice Pérol, Christos Chouaid, Clarisse Audigier-Valette, S. Schneider, David Planchard, Roland Schott, Matthieu Carton, Tina Lamy, Nicolas Girard, Thomas Filleron, M. Robain, Gaëtane Simon, Capucine Baldini, Michael Bringuier, Benjamin Besse, Xavier Quantin
Publikováno v:
Annals of Oncology. 32:S1243-S1244
Autor:
Isabelle Martel-Laffay, Alain Vergnenegre, Radj Gervais, Paul Lesueur, Christos Chouaid, Alexandre Escande, Roland Schott, M. Kissel, Chrystel Locher
Publikováno v:
Expert Review of Anticancer Therapy. 18:1159-1165
Cisplatin-based chemotherapy administered concomitantly to thoracic radiotherapy is the treatment recommended by the European guidelines for fit patients with unresectable stage III non-small cell lung cancer (NSCLC). Cisplatin may be combined with e
Autor:
Joris Mallard, Elyse Hucteau, Roland Schott, Thierry Petit, Martin Demarchi, Christine Belletier, Meher Ben Abdelghani, Hélène Carinato, Pascale Chiappa, Cathie Fischbach, Michal Kalish-Weindling, Audren Bousinière, Stéphane Dufour, Fabrice Favret, Xavier Pivot, Thomas J. Hureau, Allan F. Pagano
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
Background. Cancer cachexia and exacerbated fatigue represent two hallmarks in cancer patients, negatively impacting their exercise tolerance and ultimately their quality of life. However, the characterization of patients’ physical status and exerc